List of bibliographic references
Number of relevant bibliographic references: 6.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Advanced stage |
| 3 | Aged |
| 3 | Chemotherapy |
| 3 | Humans |
| 3 | Male |
| 3 | Prostatic Neoplasms, Castration-Resistant (drug therapy) |
| 3 | Prostatic Neoplasms, Castration-Resistant (mortality) |
| 3 | Prostatic Neoplasms, Castration-Resistant (pathology) |
| 2 | Abiraterone |
| 2 | Antineoplastic Agents, Hormonal (adverse effects) |
| 2 | Antineoplastic Agents, Hormonal (therapeutic use) |
| 2 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 2 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 2 | Bone Neoplasms (drug therapy) |
| 2 | Bone Neoplasms (mortality) |
| 2 | Bone Neoplasms (secondary) |
| 2 | Disease Progression |
| 2 | Disease-Free Survival |
| 2 | Double-Blind Method |
| 2 | Human |
| 2 | Kaplan-Meier Estimate |
| 2 | Metastasis |
| 2 | Metastatic |
| 2 | Middle Aged |
| 2 | Prednisone (therapeutic use) |
| 2 | Proportional Hazards Models |
| 2 | Prostate cancer |
| 2 | Risk Factors |
| 2 | Time Factors |
| 2 | Treatment |
| 2 | Treatment Outcome |
| 1 | Abiraterone Acetate |
| 1 | Abiraterone Acetate (adverse effects) |
| 1 | Abiraterone Acetate (therapeutic use) |
| 1 | Acetate |
| 1 | Androstenes (administration & dosage) |
| 1 | Androstenes (adverse effects) |
| 1 | Androstenes (therapeutic use) |
| 1 | Antineoplastic Agents, Hormonal (administration & dosage) |
| 1 | Antineoplastic Combined Chemotherapy Protocols |
| 1 | Antineoplastic agent |
| 1 | Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology) |
| 1 | Bone Density Conservation Agents (adverse effects) |
| 1 | Bone Density Conservation Agents (therapeutic use) |
| 1 | Bronchopulmonary |
| 1 | Castration |
| 1 | Clinical Trials, Phase III as Topic |
| 1 | Cytochrome P-450 Enzyme Inhibitors (administration & dosage) |
| 1 | Cytochrome P-450 Enzyme Inhibitors (adverse effects) |
| 1 | Drug Administration Schedule |
| 1 | Enzyme inhibitor |
| 1 | Epidermal growth factor receptor |
| 1 | Follow-Up Studies |
| 1 | Improvement |
| 1 | Long term |
| 1 | Medicine |
| 1 | Multicenter Studies as Topic |
| 1 | Neoplasm Metastasis |
| 1 | Neoplasm Staging |
| 1 | Neoplasms, Hormone-Dependent (drug therapy) |
| 1 | Neoplasms, Hormone-Dependent (enzymology) |
| 1 | Neoplasms, Hormone-Dependent (mortality) |
| 1 | Neoplasms, Hormone-Dependent (pathology) |
| 1 | Nephrology |
| 1 | Odds Ratio |
| 1 | Oral administration |
| 1 | Phase I trial |
| 1 | Prednisone (administration & dosage) |
| 1 | Prognosis |
| 1 | Prostatic Neoplasms, Castration-Resistant (enzymology) |
| 1 | Protein-tyrosine kinase |
| 1 | Quality of life |
| 1 | Randomized Controlled Trials as Topic |
| 1 | Resistance |
| 1 | Retrospective Studies |
| 1 | Solid tumor |
| 1 | Steroid 17-alpha-Hydroxylase (antagonists & inhibitors) |
| 1 | Steroid 17-alpha-Hydroxylase (metabolism) |
| 1 | Steroid Synthesis Inhibitors (adverse effects) |
| 1 | Steroid Synthesis Inhibitors (therapeutic use) |
| 1 | Survival Rate |
| 1 | Symptomatology |
| 1 | Toxicity |
| 1 | Treatment efficiency |
| 1 | Urology |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/UK/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "Eric J. Small"
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i \
-Sk "Eric J. Small" \
| HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= UK
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Eric J. Small
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
